- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00493454
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma
Primary Objective:
- Overall Response Rate (ORR).
Secondary Objectives:
- The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders.
- Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR).
- Time to next anticancer therapy (TTNT).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
^90 Y Ibritumomab tiuxetan and rituximab are both designed to attach to lymphoma cells, causing them to die.
Before you can start treatment on this study, you will have what are called "screening tests." These tests will help the doctor decide if you are eligible to take part in this study. You will have a physical exam. Your blood (about 2 to 3 teaspoons) and urine will be collected for routine tests. You will have a chest x-ray and computerized tomography (CT) scans of the neck, chest, abdomen, and pelvis. You will have a bone marrow aspirate and biopsy performed. To collect a bone marrow aspirate and biopsy, an area of the hip or chest bone is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn through a large needle. Women who are able to have children must have a negative blood pregnancy test.
The study doctors will first make sure that your disease has not spread too much and is not too severe to require immediate treatment with chemotherapy before you can begin treatment on this study. If you are found to be eligible to take part in this study, you will be given Benadryl (diphenhydramine) by vein, and you will be given Tylenol (acetaminophen) by mouth before each dose of rituximab. This is done to help decrease the risk of developing side effects of rituximab. You will then receive 1 dose of rituximab by vein over 6 to 8 hours on Day 1 of treatment. After treatment with rituximab, you will then be given a radioactive antibody, ^111 In Ibritumomab tiuxetan (this is a radioactive agent that binds to rituximab to help with imaging exams), by vein over about 10 minutes. This is so researchers can use a special camera to see where the drug is in your body.
You will have imaging performed (with the special camera) on Day 1 and on either Day 2 or Day 3. On Day 8, you will receive a second dose of rituximab. This will then be followed by a dose ^90 Y Ibritumomab tiuxetan of given by vein over 10 minutes. This completes the treatment.
If you experience intolerable side effects while on this study, you may be removed from this study. The study doctor will then offer other treatment options to you.
For your follow-up, you will have blood (about 2 tablespoons) drawn once a week for the first 3 months, then every 3 months for 1 year, and then every 4 months for the second year. At these visits, you may also have CT scans, x-rays, and bone marrow biopsies and aspirates performed, if needed.
This is an investigational study. ^90 Y Ibritumomab tiuxetan and rituximab have been approved by the FDA for the treatment of indolent B-cell lymphoma. Up to 35 patients will take part in this multicenter study. Up to 15 will be enrolled at M. D. Anderson.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- UT MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study initiation, and fully recovered from acute toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
- Previously treated patients with a histology of refractory/relapsed indolent lymphomas including: (a) Extranodal marginal lymphoma of MALT type; (b) Nodal Marginal zone B-cell lymphoma (+/- monocytoid cells); (c) Splenic marginal B-cell lymphoma (+/- villous lymphocytes).
- Signed informed consent
- Age >/= 18 years
- Expected survival >/= 3 months
- Pre-study Zubrod performance status of 0, 1, or 2
- Acceptable hematologic status within two weeks prior to patient registration, including: (a) Absolute neutrophil count ([segmented neutrophils + bands] * total white blood count (WBC)) >/= 1,500/mm^3; (b) Platelet counts >/= 100,000/mm^3.
- Female patients who are not pregnant or lactating
- Men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician)
- Patients previously on Phase II drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
- Patients determined to have < 25% bone marrow involvement with lymphoma within six weeks of registration (define measurement of a bone marrow aspirate or biopsy) (This criteria must be strictly met for adequate patient safety.)
- Patient should have at least one lesion measuring >/= 2 cm in a single dimension.
Exclusion Criteria:
- Prior myeloablative therapies with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue.
- Platelet count< 100,000 cells/mm^3.
- Presence of hypocellular bone marrow.
- Patients with history of failed stem cell collection.
- Prior radioimmunotherapy
- Presence of Central Nervous System (CNS) lymphoma
- Patients with HIV.
- Patients with pleural effusion
- Patients with abnormal liver function: total bilirubin > 2.0 mg/dL
- Patients with abnormal renal function: serum creatinine > 2.0 mg/dL
- Patients who have received prior external beam radiation therapy to > 25% of active bone marrow (involved field or regional)
- Patients who have received short-acting growth factor support (Leukine, Neupogen, Procrit) within 2 weeks prior to treatment or long-acting growth-factor support (Aranesp), Neulasta) within 4 weeks prior to treatment.
- Serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives
- Major surgery, other than diagnostic surgery, within four weeks
- Evidence of transformation in the latest biopsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibritumomab tiuxetan + Rituximab
Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
|
.3 mCi IV Over 10 Minutes x 1 Day
Other Names:
250 mg/m^2 IV Over 6 to 8 Hours
1.6 mg IV Over 10 Minutes x 1 Day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: Evaluation 4 weeks after administration of Zevalin up to 3 years
|
Objective response rate (ORR) = number of participants out of all participating with Complete Response (CR) + Partial Response (PR) as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial response (PR) must have ≥ 30% decrease in the sum of longest diameter of all target lesions, from the baseline sum.
Complete response (CR) must have disappearance of all target and non-target lesions.
Response assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scans, every 3 months for the first year and every 6 months up to 3 years following.
|
Evaluation 4 weeks after administration of Zevalin up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
- Antibodies, Monoclonal
Other Study ID Numbers
- 2005-0571
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsNot yet recruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
Juno Therapeutics, a Subsidiary of CelgeneActive, not recruitingFollicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell LymphomaUnited States
Clinical Trials on Zevalin
-
Lymphoma Study AssociationCompletedB-Cell LymphomaFrance, Belgium, Switzerland
-
Soroka University Medical CenterUnknown
-
Chulalongkorn UniversityBayerTerminatedDiffuse Large B-cell LymphomaThailand
-
BayerCompletedNon-Hodgkin's Lymphoma (NHL)Japan
-
Spectrum Pharmaceuticals, IncTerminatedDiffuse Large B-cell Lymphoma | Follicle Center LymphomaUnited States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
-
Spectrum Pharmaceuticals, IncBayerCompleted
-
BayerCompletedLymphoma, Follicular | Non-Hodgkin LymphomaBelgium
-
A.O. Ospedale Papa Giovanni XXIIIRegional Hospital of BolzanoTerminatedLymphoma, Non-HodgkinItaly
-
Tufts Medical CenterSpectrum Pharmaceuticals, IncTerminatedMultiple MyelomaUnited States
-
University Hospital, BordeauxBayerCompletedDiffuse Large B-Cell Lymphoma | Mantle Cell LymphomaFrance